Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Either bevacizumab or EGFR antibodies

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-t... Author: imedex Added: 10/13/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts